If the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe please get in touch via Contact@EBiSC.org.

SIGi001-A-12

iPSC0028 - BiAllelic MAPT_Ex10+16T/Clone 1F5-D12, SAMEA104237570

Gene-edited iPSC line

Not-for-profit fee: £1700 per vial
Immediately available for distribution*
*Once all legal and processing details completed
Timepoint: Confluence
Magnification: 4x
Timepoint: Confluence
Magnification: 10x
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name SIGi001-A-12
Alternative name(s)
iPSC0028 - BiAllelic MAPT_Ex10+16T/Clone 1F5-D12, SAMEA104237570
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
SIGi001-A-3
(iPSC0028 MAPT P301L C4)
SIGi001-A-4
(iPSC0028 MAPT P301L D4)
SIGi001-A-5
(iPSC0028 MAPT P301S 1C9C4)
SIGi001-A-6
(iPSC0028 MAPT P301S 1B9C9)
SIGi001-A-7
(iPSC0028 MAPT P301S 2G2B7)
SIGi001-A-8
(iPSC0028 MAPT P301S+Ex10+16/Clone 7D11A7)
SIGi001-A-9
(iPSC0028 MAPT P301S+Ex10+16/Clone 7H6A1)
SIGi001-A-10
(iPSC0028 MAPT P301S+Ex10+16/Clone 7G4A8)
SIGi001-A-11
(iPSC0028 MAPT P301S+Ex10+16/Clone 7C6A4, SAMEA4451118)
SIGi001-A-16
(SIGi001-A-9 Bi-Allelic MAPT HA-tag)
SIGi001-A-13
(iPSC0028 – MonoAllelic MAPT_Ex10+16T/Clone 1D01-11)
SIGi001-A-1
(iPSC0028 SLC17A7/GFP E3)
SIGi001-A-2
(iPSC0028 SLC17A7/GFP C3)
SIGi001-A-14
(SIGi001-A Bi-Allelic MAPT HA-tag)
SIGi001-A-15
(SIGi001-A Dox inducible NGN2)
SIGi001-A-17
(SIGi001-A-9 Dox inducible NGN2)
SIGi001-A-18
(SIGi001-A-12 Bi-Allelic MAPT HA-tag #U28-12-P29-5)
SIGi001-A-19
(SIGi001-A-12 Dox inducible NGN2)
Notes The parental iPSC line SIGi001-A can be sourced via Sigma as 'iPSC0028'.

Provider

Depositor Sigma-Aldrich (SIG)
Distributors
EBiSC

External Databases

hPSCreg SIGi001-A-12
BioSamples SAMEA104237570
Cellosaurus CVCL_LL41
Wikidata Q54953434

General Information

Publications View all related publications on hPSCreg (1)
This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of (not in EBiSC, see SIGi001-A in hPSCreg)

Donor Information#

General Donor Information

Sex female
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Family history no
Is the medical history available upon request? no
Is clinical information available? no

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA4447434

hIPSC Derivation#

General

More source cell information can be found in the parental cell line SIGi001-A in hPSCreg.

Reprogramming method

Vector type Integrating
Vector Virus (Retrovirus)
Genes
Is the used vector excisable?
No
Absence of reprogramming vector(s)?
Yes
Reprogramming vectors silenced?
Unknown
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Latest released batch

Culture medium mTeSR-1
Passage method EDTA
Surface coating Matrigel
O2 concentration 20
CO2 concentration 5
Temperature 37
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
TRA 1-60
Yes
POU5F1 (OCT-4)
Yes
SSEA-3
Yes
EB: qPCR expression of PAX6, NEUROD, TBX5, GATA6 ,AFP, SERPINA and GAPDH
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
Mesoderm
Ont Id: UBERON_0000926
Ectoderm
Ont Id: UBERON_0000924

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Sterility

Inoculation for microbiological growth No Contaminants Detected
Mycoplasma Not Detected
Viability Viable post-cryopreservation

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XY
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
Whole genome sequencing
https://ega-archive.org/studies/EGAS00001002755
This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768

Genetic Modification#

Disease/phenotype related modifications
Synonyms
  • FTD
Genetic modifications
MAPT (target)
Isogenic modification
17q21.31
Homozygous
1F05-12 (IVS10+16 biallelic)
Mutated